LifeSci Advisors is a Biotech Investor Relations consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Pharmaceutical Investor Relations consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is an Equity Research consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Corporate Communications consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Biotechnology consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Biotech Investor Relations consultancy that provides equity research to clients in medical life sciences. LifeSci Advisors is a Pharmaceutical Investor Relations consultancy that provides equity research to clients in medical life sciences. LifeSci Advisors is an Investor Relations consultancy that provides equity research to clients in Healthcare LifeSci Advisors is an Equity Research consultancy that provides equity research to clients in Pharmaceuticals. LifeSci Advisors is a Corporate Communications consultancy that provides equity research to clients in Medical Devices. LifeSci Advisors is a Healthcare Investor consultancy that provides equity research to clients in Medical Devices. LifeSci Advisors is a Pharmaceutical Investor consultancy that provides equity research to clients in Medical Devices.

Web developed by Bolinger web design

Our Distribution


IPH.PA: Phase 1 IPH21/Anti-PD1 Combo Study in Solid Tumors Announced by BMS


« Back to News



Report is Available for Download at: www.lifesciadvisors.com/clients/innate

Previously, we discussed the IPH21 Phase 1 data that was reported by Innate Pharma and concluded that it justified further clinical studies. Innate’s development partner, Bristol-Myers Squibb (NYSE: BMY; “BMS”), just announced the company’s first clinical trial with IPH21, which will be in combination with an anti-PD1 antibody in patients with five different forms of advanced solid tumors.

Safety and Efficacy to be Measured of IPH21/Anti-PD1 Combo in Phase 1 BMS Study. The aim of the Phase 1 study that was just announced by BMS is to determine the safety and clinical activity of the IPH21/BMS-936558 combination treatment. BMS-936558 is a fully-human antibody that targets the inhibitory receptor expressed on activated T-cells called PD-1 or programmed death-1. Thus the primary outcome will be safety with the secondary outcomes including a preliminary assessment of efficacy that will be measured by tumor assessment.

« Back to News

Contact Us   |   About Us   |   Privacy Policy   |   Disclaimer  |   Careers

©2014 LifeSci Advisors, LLC. All Rights Reserved.

email


Web developed by Bolinger web design